This excerpt taken from the ACL 6-K filed Jul 24, 2008.
Patanase® began subsequent to its FDA approval in April 2008.
The improvement in the other pharmaceuticals/rebates line for the six months ended June 30, 2008 compared to 2007 was the result of growth in sales of various miscellaneous products and a reduction in sales return provisions. This was partially offset by changes in a U.S. government rebate program. During the six months ended June 30, 2007, we recognized approximately $7.9 million for reimbursement we received related to rebates. We paid the rebates prior to October 2006 under the TRICARE rebate program, which was discontinued. This rebate program was reinstated for eligible sales beginning in January 2008.
Global sales of our surgical products grew 20.9% (12.6% in constant currency) to $1,466.6 million in the six months ended June 30, 2008, compared to 2007. Higher sales of intraocular lenses, as well as other cataract and vitreoretinal products (which include surgical equipment, devices and disposable products), accounted for most of the growth. The acquisition of a majority interest in WaveLight AG in November 2007 expanded sales of our refractive products for this period in 2008.
Sales of intraocular lenses increased 23.6% in the six months ended June 30, 2008. This increase reflected continued growth in the market and in our market share, as well as the shift in demand from lower-priced intraocular lenses to the AcrySof®
This excerpt taken from the ACL 6-K filed Apr 24, 2008.
Patanase® nasal spray for the treatment of symptoms of seasonal allergic rhinitis in patients twelve years of age or older. Recently, the FDA issued an approvable letter informing the Company that additional information will be required to support the approval of
This excerpt taken from the ACL 20-F filed Mar 18, 2008.
Patanase® product NDA during 2007. That application is presently under review at the agency and a response is expected in 2008.
This excerpt taken from the ACL 20-F filed Mar 19, 2007.
Patanase® and have completed enrollment of a clinical trial to support amending our NDA in 2007.
In the otic area, we are developing a new anti-infective/anti-inflammatory combination for treating ear infections.